These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 14638523)

  • 1. Should evidence-based proof of efficacy as defined for a specific therapeutic agent be extrapolated to encompass a therapeutic class of agents?
    Antman EM; Ferguson JJ
    Circulation; 2003 Nov; 108(21):2604-7. PubMed ID: 14638523
    [No Abstract]   [Full Text] [Related]  

  • 2. Should evidence-based proof of drug efficacy be extrapolated to a "class of agents"?
    Furberg CD; Psaty BM
    Circulation; 2003 Nov; 108(21):2608-10. PubMed ID: 14638524
    [No Abstract]   [Full Text] [Related]  

  • 3. [Ranking the efficacy of drugs--a question of "class"? It is difficult to determine equivalency of two different treatments].
    Liedholm H; Linné AB
    Lakartidningen; 2002 Sep; 99(36):3492-4, 3497-9, 3502. PubMed ID: 12362748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The risks of substitution of therapeutic modalities by cheaper and sometimes less effective agents.
    Brook I
    Arch Intern Med; 1990 Mar; 150(3):688-9. PubMed ID: 2310291
    [No Abstract]   [Full Text] [Related]  

  • 5. Therapeutic substitution: guilty until proven innocent.
    Kereiakes DJ; Willerson JT
    Circulation; 2003 Nov; 108(21):2611-2. PubMed ID: 14638525
    [No Abstract]   [Full Text] [Related]  

  • 6. Drugs and the elderly. Product-to-product variability.
    Todd B
    Geriatr Nurs; 1985; 6(1):57-8. PubMed ID: 3843831
    [No Abstract]   [Full Text] [Related]  

  • 7. Genesis of generic drugs.
    Calesnick B; Kreider LA; Dinan A
    Pa Med; 1986 Dec; 89(12):32, 34, 36. PubMed ID: 3808720
    [No Abstract]   [Full Text] [Related]  

  • 8. Generic substitution: the use of medicinal products containing different salts and implications for safety and efficacy.
    Verbeeck RK; Kanfer I; Walker RB
    Eur J Pharm Sci; 2006 May; 28(1-2):1-6. PubMed ID: 16413762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progressive applications of dissolution, its impact, and implications in the pharmaceutical world.
    Shah VP
    J Pharm Sci; 2013 Sep; 102(9):2895-7. PubMed ID: 23728620
    [No Abstract]   [Full Text] [Related]  

  • 10. [Therapeutic alternatives equivalent: in the eye of the hurricane].
    López Briz E; Alegre del Rey E; Fraga Fuentes MD; Clopés Esela A; Bautista Paloma J; Ortega Eslava A;
    Farm Hosp; 2013; 37(4):273-5. PubMed ID: 24010687
    [No Abstract]   [Full Text] [Related]  

  • 11. Quality indicators for medication use in vulnerable elders.
    Shrank WH; Polinski JM; Avorn J
    J Am Geriatr Soc; 2007 Oct; 55 Suppl 2():S373-82. PubMed ID: 17910560
    [No Abstract]   [Full Text] [Related]  

  • 12. Procedures and methods of benefit assessments for medicines in Germany: give the child a name.
    Schünemann H; Kunz R; Falck-Ytter Y; Santesso N
    Eur J Health Econ; 2009 May; 10(2):237-8. PubMed ID: 19290557
    [No Abstract]   [Full Text] [Related]  

  • 13. Publishing the evidence for children's medicines.
    Choonara I; Bauchner H
    Arch Dis Child; 2008 Oct; 93(10):815. PubMed ID: 18809700
    [No Abstract]   [Full Text] [Related]  

  • 14. Are drugs within a class interchangeable?
    Furberg CD; Herrington DM; Psaty BM
    Lancet; 1999 Oct; 354(9185):1202-4. PubMed ID: 10513728
    [No Abstract]   [Full Text] [Related]  

  • 15. Gene medication or genetic modification? The devil is in the details.
    Foss GS; Rogne S
    Nat Biotechnol; 2003 Nov; 21(11):1280-1. PubMed ID: 14595352
    [No Abstract]   [Full Text] [Related]  

  • 16. Bioequivalence studies: a new EMA guideline.
    Houin G
    Arzneimittelforschung; 2010; 60(4):169-70. PubMed ID: 20486464
    [No Abstract]   [Full Text] [Related]  

  • 17. [For the sake of quality].
    Pijpers A
    Tijdschr Diergeneeskd; 1994 Aug; 119(14-15):432-8. PubMed ID: 8066580
    [No Abstract]   [Full Text] [Related]  

  • 18. Current standards in reported drug trials.
    Reiffenstein RJ; Schiltroth AJ; Todd DM
    Can Med Assoc J; 1968 Dec; 99(23):1134-5. PubMed ID: 4881692
    [No Abstract]   [Full Text] [Related]  

  • 19. Response to the expertise: procedures and methods of benefit assessments for medicines in Germany, by Geertruida E. Bekkering and Jos Kleijnen.
    Koch K; Lange S
    Eur J Health Econ; 2009 May; 10(2):233-6. PubMed ID: 19123011
    [No Abstract]   [Full Text] [Related]  

  • 20. Generic equivalency: does it exist?
    Payne RJ
    Med Ann Dist Columbia; 1969 Sep; 38(9):490-2. PubMed ID: 5259629
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.